Antipsychotic polypharmacy increases metabolic dysregulation in female rats

Experimental and Clinical Psychopharmacology

Volumn 21, Issue 2, 2013, Pages 164-171

  Boyda, Heidi N ^a   Procyshyn, Ric M ^a   Tse, Lurdes ^a   Xu, James ^a   Jin, Chen Helen ^a   Wong, Daniel ^a   Pang, Catherine C Y ^a   Honer, William G ^a   Barr, Alasdair M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antipsychotic; Dysregulation; Female rats; Glucose; Insulin; Metabolic; Polypharmacy

Indexed keywords

CLOZAPINE; GLUCOSE; HALOPERIDOL; INSULIN; RISPERIDONE;

ACCURACY; ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLIC DISORDER; NONHUMAN; POLYPHARMACY; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; FEMALE; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; METABOLISM; POLYPHARMACY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84876140983     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0031228     Document Type: Article

References (46)

1. Albaugh, V. L., Henry, C. R., Bello, N. T., Hajnal, A., Lynch, S. L., Halle, B., & Lynch, C. J. (2006). Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring), 14, 36-51. doi:10.1038/oby.2006.6
2. Assié, M. B., Carilla-Durand, E., Bardin, L., Maraval, M., Aliaga, M., Malfetes, N.,...Newman-Tancredi, A. (2008). The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: Comparison with aripiprazole, ziprasidone, bifeprunox and F15063. European Journal of Pharmacology, 592, 160-166. doi: 10.1016/j.ejphar.2008.06.105
3. Baptista, T., Araujo de Baptista, E., Ying Kin, N. M., Beaulieu, S., Walker, D., Joober, R.,...Richard, D. (2002). Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: Bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Research, 957, 144-151. doi:10.1016/S0006-8993(02)03616-8
4. Baptista, T., Lacruz, A., Paez, X., Hernandez, L., & Beaulieu, S. (2002). The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? European Journal of Pharmacology, 447, 91-98. doi:10.1016/S0014-2999(02)01816-2
5. Barnes, T. R., & Paton, C. (2011). Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs, 25, 383-399. doi:10.2165/ 11587810-000000000-00000
6. Barr, A. M., Young, C. E., Sawada, K., Trimble, W. S., Phillips, A. G., & Honer, W. G. (2004). Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: Relevance to neural connectivity in schizophrenia. European Journal of Neuroscience, 20, 303-307. doi:10.1111/j.0953-816X.2004.03457.x
7. Boyda, H. N., Procyshyn, R. M., Tse, L., Hawkes, E., Jin, C. H., Pang, C.C.,...Barr, A. M. (2012). Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. Journal of Psychiatry and Neuroscience, 37, 407-415. doi:10.1503/jpn.110140
8. Boyda, H. N., Procyshyn, R. M., Tse, L., Wong, D., Pang, C. C., Honer, W. G., & Barr, A. M. (2012). Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology, 62, 1391-1400. doi:10.1016/j.neuropharm.2011.02.019
9. Boyda, H. N., Tse, L., Procyshyn, R. M., Honer, W. G., & Barr, A. M. (2010). Preclinical models of antipsychotic drug-induced metabolic side effects. Trends in Pharmacological Sciences, 31, 484-497. doi:10.1016/ j.tips.2010.07.002
10. Boyda, H. N., Tse, L., Procyshyn, R. M., Wong, D., Wu, T. K., Pang, C. C., & Barr, A. M. (2010). A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 945-954. doi:10.1016/j.pnpbp.2010.04.024
11. Chintoh, A. F., Mann, S. W., Lam, L., Giacca, A., Fletcher, P., Nobrega, J., & Remington, G. (2009). Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model. Schizophrenia Research, 108, 127-133. doi:10.1016/j.schres.2008.12.012
12. Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research, 89, 91-100. doi:10.1016/j.schres.2006.08.017
13. Fleischhacker, W. W. & Uchida, H. (2012). Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. International Journal of Neuropsychopharmacology, 1-11. doi:10.1017/ S1461145712000399
14. Gallego, J. A., Bonetti, J., Zhang, J., Kane, J. M., & Correll, C. U. (2012). Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research, 138, 18-28. doi:10.1016/j.schres .2012.03.018
15. Gallego, J. A., Nielsen, J., De Hert, M., Kane, J. M., & Correll, C. U. (2012). Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety, 11, 527-542. doi:10.1517/14740338.2012 .683523
16. Gohlke, J. M., Dhurandhar, E. J., Correll, C. U., Morrato, E. H., Newcomer, J. W., Remington, G.,...Allison, D. B. (2012). Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Frontiers in Psychiatry, 3, 62.
17. Hem, A., Smith, A. J., & Solberg, P. (1998). Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink. Laboratory Animals, 32, 364-368. doi:10.1258/ 002367798780599866
18. Honer, W. G., Procyshyn, R. M., Chen, E. Y., MacEwan, G. W., & Barr, A. M. (2009). A translational research approach to poor treatment response in patients with schizophrenia: Clozapine-antipsychotic polypharmacy. Journal of Psychiatry & Neuroscience, 34, 433-442.
19. Honer, W. G., Thornton, A. E., Chen, E. Y., Chan, R. C., Wong, J. O., Bergmann, A.,...Clozapine and Risperidone Enhancement (CARE) Study Group. (2006). Clozapine alone versus clozapine and risperidone with refractory schizophrenia. The New England Journal of Medicine, 354, 472-482. doi:10.1056/NEJMoa053222
20. Honer, W. G., Thornton, A. E., Sherwood, M., MacEwan, G. W., Ehmann, T. S., Williams, R.,...Barr, A. M. (2007). Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs, 21, 699-714. doi:10.2165/ 00023210-200721090-00001
21. Houseknecht, K. L., Robertson, A. S., Zavadoski, W., Gibbs, E. M., Johnson, D. E., & Rollema, H. (2007). Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: Implications for adverse metabolic effects. Neuropsychopharmacology, 32, 289-297. doi:10.1038/sj.npp.1301209
22. Huang, M. C., Lu, M. L., Tsai, C. J., Chen, P. Y., Chiu, C. C., Jian, D. L.,. . . Chen, C. H. (2009). Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatrica Scandinavica, 120, 274-280. doi:10.1111/j.1600-0447 .2009.01401.x
23. Kapur, S., & Remington, G. (2001). Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annual Review of Medicine, 52, 503-517. doi:10.1146/annurev.med.52.1.503
24. Krane-Gartiser, K., Breum, L., Glumrr, C., Linneberg, A., Madsen, M., Koster, A.,...Fink-Jensen, A. (2011). Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nordic Journal of Psychiatry, 65, 345-352. doi:10.3109/08039488.2011 .565799
25. Leung, J. Y., Barr, A. M., Procyshyn, R. M., Honer, W. G., & Pang, C. C. (2012). Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system. Pharmacology and Therapeutics, 135, 113-122. doi:10.1016/j.pharmthera.2012.04.003
26. Lykkegaard, K., Larsen, P. J., Vrang, N., Bock, C., Bock, T., & Knudsen, L. B. (2008). The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophrenia Research, 103, 94-103. doi:10.1016/j.schres.2008.05.011
27. Maayan, L., & Correll, C. U. (2011). Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21, 517-535. doi:10.1089/cap.2011.0015
28. Misawa, F., Shimizu, K., Fujii, Y., Miyata, R., Koshiishi, F., Kobayashi, M.,...Kashima, H. (2011). Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry, 11, 118. doi:10.1186/1471-244X-11-118
29. Mukherjee, J., Christian, B. T., Narayanan, T. K., Shi, B., & Mantil, J. (2001). Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology, 25, 476-488. doi:10.1016/S0893-133X(01)00251-2
30. Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2007). Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. American Journal of Physiology Endocrinology and Metabolism, 294, E15-E26. doi:10.1152/ ajpendo.00645.2007
31. Nasrallah, H. A. (2008). Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles. Molecular Psychiatry, 13, 27-35. doi:10.1038/sj.mp.4002066
32. Natesan, S., Reckless, G. E., Barlow, K. B., Nobrega, J. N., & Kapur, S. (2008). Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophrenia Research, 105, 224-235. doi:10.1016/j.schres.2008.07.005
33. Newcomer, J. W. (2007). Antipsychotic medications: Metabolic and cardiovascular risk. Journal of Clinical Psychiatry, 68, 8-13.
34. Pani, L., Pira, L., & Marchese, G. (2007). Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. European Psychiatry, 22, 267-275. doi:10.1016/j.eurpsy.2007.02.005
35. Park, S., Sang Mee, H., Il Sung, A., & Sung Hoon, K. (2010). Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them. Journal of Psychopharmacology, 24, 1105-1114. doi:10.1177/0269881109348167
36. Procyshyn, R. M., Honer, W. G., Wu, T. K., Ko, R. W., McIsaac, S. A., Young, A. H.,. . . Barr, A. M. (2010). Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: A review of medication profiles in 435 Canadian outpatients. Journal of Clinical Psychiatry, 71, 566-573. doi:10.4088/JCP .08m04912gre
37. Procyshyn, R. M., Wasan, K. M., Thornton, A. E., Barr, A. M., Chen, E. Y., Pomarol-Clotet, E.,...Clozapine and Risperidone Enhancement Study Group. (2007). Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. Journal of Psychiatry & Neuroscience, 32, 331-338.
38. Skrede, S., Ferno, J., Vazquez, M. J., Fjaer, S., Pavlin, T., Lunder, N.,... Steen, V. M. (2012). Olanzapine, but not aripiprazole, weightindependently elevates serum triglycerides and activates lipogenic gene expression in female rats. International Journal of Neuropsychopharmacology, 15, 163-179. doi:10.1017/S1461145711001271
39. Smith, G. C., Chaussade, C., Vickers, M., Jensen, J., & Shepherd, P. R. (2008). Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia, 51, 2309-2317. doi:10.1007/ s00125-008-1152-3
40. Smith, G. C., Vickers, M. H., Cognard, E., & Shepherd, P. R. (2009). Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour. Schizophrenia Research, 115, 30-40. doi:10.1016/j.schres.2009.07.011
41. Smith, G. C., Vickers, M. H., & Shepherd, P. R. (2011). Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Archives of Physiology and Biochemistry, 117, 241-249. doi:10.3109/13813455.2011.576681
42. Tulipano, G., Rizzetti, C., Bianchi, I., Fanzani, A., Spano, P., & Cocchi, D. (2007). Clozapine-induced alteration of glucose homeostasis in the rat: The contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology, 85, 61-70. doi:10.1159/000100981
43. Urichuk, L., Prior, T. I., Dursun, S., & Baker, G. (2008). Metabolism: Clinical and Experimental of atypical antipsychotics: Involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Current Drug Metabolism, 9, 410-418. doi:10.2174/138920008784746373
44. Victoriano, M., Hermier, D., Even, P. C., Fromentin, G., Huneau, J. F., Tome, D., & de Beaurepaire, R. (2009). Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. Psychopharmacology (Berlin), 206, 167-176. doi:10.1007/s00213-009-1593-5
45. Weston-Green, K., Huang, X. F., & Deng, C. (2010). Sensitivity of the female rat to olanzapine-induced weight gain-far from the clinic? Schizophrenia Research, 116, 299-300. doi:10.1016/j.schres.2009.09 .034
46. Zink, M., Englisch, S., & Meyer-Lindenberg, A. (2010). Polypharmacy in schizophrenia. Current Opinion in Psychiatry, 23, 103-111. doi: 10.1097/YCO.0b013e3283366427